Clinical Trials Using Live-Attenuated Listeria Encoding Human Mesothelin Vaccine CRS-207

Clinical trials are research studies that involve people. The clinical trials on this list are studying Live-Attenuated Listeria Encoding Human Mesothelin Vaccine CRS-207. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-2 of 2
  • CRS-207, Nivolumab, and Ipilimumab with or without A Vaccine (GVAX Pancreas Vaccine) and Cyclophosphamide in Treating Patients with Metastatic Pancreatic Ductal Cancer

    This phase II trial studies how well CRS-207, nivolumab, and ipilimumab with or without GVAX pancreas vaccine and cyclophosphamide work in treating patients with pancreatic ductal cancer that has spread to other places in the body. Vaccines made from inserting a laboratory-treated gene into a person's tumor cells, such as CRS-207, may help the body build an effective immune response to kill tumor cells that express mesothelin. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. GVAX pancreas vaccine is made by putting the GM-CSF gene into the pancreatic cancer cells. GM-CSF helps to activate immune system cells to recognize and attack their cancer cells. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving CRS-207, nivolumab, and ipilimumab with or without GVAX pancreas vaccine and cyclophosphamide will work better in treating patients with pancreatic ductal cancer.
    Location: Johns Hopkins University / Sidney Kimmel Cancer Center, Baltimore, Maryland

  • Epacadostat, Pembrolizumab, and CRS-207 with or without Cyclophosphamide and a Vaccine (GVAX Pancreas Vaccine) in Treating Patients with Metastatic Pancreatic Cancer

    This phase II trial studies the side effects and best dose of epacadostat and to see how well it works when given together with pembrolizumab and CRS-207 with or without cyclophosphamide and GVAX pancreas vaccine in treating patients with pancreatic cancer that has spread to other places in the body. Epacadostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. CRS-207 may cause the immune system to attack cells with mesothelin, which may then kill cancer cells. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Proteins in GVAX pancreas vaccine may help to activate the immune system cells (the body’s system to fight infection or disease) to recognize and attack cancer cells. It is not yet known whether given epacadostat, pembrolizumab, and CRS-207 with cyclophosphamide and GVAX pancreas vaccine works better in treating patients with pancreatic cancer.
    Location: Johns Hopkins University / Sidney Kimmel Cancer Center, Baltimore, Maryland